| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology | ||
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | -% | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Integer Holdings Corporation$89.54
-0.56 (-0.62%)
Market Cap
3.03 B
EPS
4.06
P/E Ratio
22.25 $
Value Trade
51.28 M
SEC Financials
Q2 2026Dilution Risk
Revenue
439.58 M
R&D Expenses
16.24 M
Operating CF
24.70 M
Total Assets
3.41 B
Total Liabilities
1.71 B
Equity
1.70 B
D/E Ratio
12,345
-0.06 %
Week
3.66 %
1 Month
7.57 %
3 Month
29.99 %
6 Month
-5.58 %
5 Year
380.07 %
All Time
Cash Data
Cash Position
8.12 M
Monthly Burn
-
Runway
12,345 mo
Burn Trend
StableSEC Filing
Apr 30, 2026
Overview
Volume
522.84 K
52 Week Range
62 - 123.78
% held by Insiders
1.36 %
% held by Institutions
113.12 %
Enterprise Value
4.40 B
Total Shares
34.08 M
Short %
13.63 %
Float Shares
33.60 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | |||
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in ITGR
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
ITGR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ITGR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ITGR
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
ITGR Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
ITGR Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
ITGRInteger Holdings Corporation Announces Preliminary Unaudited Sales Results and Acquisition of Pulse Technologies
Integer Holdings Corporation announced its preliminary unaudited sales results for 2023, indicating a 16% increase over the previous year. The company also completed the acquisition of Pulse Technologies, which brings advanced micro machining capabilities to strengthen its position in growing markets. The acquisition is expected to be beneficial, enhancing Integer's product development capabilities and manufacturing resources. The financial details of the transaction include an estimated purchase price of approximately $140 million and expected growth in sales and EBITDA from Pulse Technologies.
Read more →ITGRFIRST AMENDMENT TO CREDIT AGREEMENT
Integer Holdings Corporation (ITGR) has amended its existing credit agreement as of January 30, 2023. The amendments involve updates to the capitalized terms and conditions, ensuring compliance with lender requirements. The agreement demonstrates a proactive approach by Integer to modify its obligations while maintaining strong relationships with lenders. This will potentially enhance their financial flexibility moving forward.
Read more →ITGRHISTORICAL FINANCIAL INFORMATION 2017 by Quarter and Total Year - 5 periods 2018 by 1st Quarter - 1 period GENERAL Non-GAAP Financial Information Discontinued Operations Reporting Important Note Regarding Financial State
2017 by Quarter and Total Year - 5 periods 2018 by 1st Quarter - 1 period HISTORICAL FINANCIAL INFORMATION PRESENTED Operations Statements and GAAP to Non-GAAP Reconciliations Bridges To Previously Reported The Company uses non-GAAP financial measures, including the measures
Read more →ITGRInteger Completes Divestiture of its Advanced Surgical and Orthopedics Product Lines FRISCO, TX
Integer Completes Divestiture of its Advanced Surgical and Orthopedics Product Lines FRISCO, TX July 02, 2018 Integer Holdings Corporation ( Integer ) (NYSE: ITGR) today announced that it has completed the previously announced sale of its Advanced Surgical and Orthopedics ( AS&
Read more →ITGRITGR 2017-16-07 PRESS RELEASE CEO Exhibit Investor Relations: Amy Wakeham IR@ integer.net 214.618.4978 FOR IMMEDIATE RELEASE Media Relations: Kelly Butler kelly.butler@integer.net 214.618.4216 Integer Announces Appointme
Investor Relations: Amy Wakeham IR@ integer.net 214.618.4978 FOR IMMEDIATE RELEASE Media Relations: Kelly Butler kelly.butler@integer.net 214.618.4216 Integer Announces Appointment of Joseph W. Dziedzic as President and Chief Executive Officer FRISCO, TEXAS, July 17, 2017 - In
Read more →ITGRInvestor Relations: Amy Wakeham IR@integer.net 214.618.4978 Media Relations: Kelly Butler kelly.butler@integer.net 214.618.4216 Integer Announces Leadership Change FRISCO, TEXAS
Integer Announces Leadership Change FRISCO, TEXAS, March 27, 2017 Integer Holdings Corporation (NYSE: ITGR), a leading medical device outsource (MDO) manufacturer, today announced that Thomas J. Hook has stepped down as Integer s President & Chief Executive Officer, effective i
Read more →ITGRGary Haire to Join Integer as Executive Vice President and Chief Financial Officer
Investor Relations: Amy Wakeham IR@ integer.net 214.618.4978 FOR IMMEDIATE RELEASE Media Relations: Kelly Butler kelly.butler@integer.net 214.618.4216 Gary Haire to Join Integer as Executive Vice President and Chief Financial Officer ~ Proven Executive Brings Strong Background
Read more →ITGRLAKE REGION MEDICAL HOLDINGS, INC. Unaudited Condensed Consolidated Balance Sheets (in thousands, except per share data)
LAKE REGION MEDICAL HOLDINGS, INC. Unaudited Condensed Consolidated Balance Sheets (in thousands, except per share data) October 3, 2015 January 3, 2015 Assets Current assets: Cash $ 52,362 $ 44,191 Accounts receivable, net of allowances of $5,037 and
Read more →ITGRAnthony Borowicz tborowicz@greatbatch.com tel 716-759-5809
Investor Relations Contact: Anthony Borowicz tborowicz@greatbatch.com tel 716-759-5809 March 14, 2016 Media Contact: Christopher Knospe cknospe@greatbatch.com tel 716-759-5727 Greatbatch Announces Completion of Nuvectra Spin-Off FRISCO, Texas Greatbatch, Inc. (NYSE: GB)
Read more →ITGRGreatbatch, Inc.
Greatbatch, Inc. Reports 2015 Fourth Quarter and Full Year Results FRISCO, Texas, Feb. 29, 2016 (GLOBE NEWSWIRE) -- Greatbatch, Inc. (NYSE:GB) today announced results for its fourth quarter and full-year ended January 1, 2016. Three Months Ended Year End January 1, January
Read more →ITGRElizabeth Cowell ecowell@greatbatch.com tel 214-618-4982 Media Contact: Christopher Knospe cknospe@greatbatch.com tel 716-759-5727
Investor Relations Contact: Elizabeth Cowell ecowell@greatbatch.com tel 214-618-4982 Media Contact: Christopher Knospe cknospe@greatbatch.com tel 716-759-5727 October 27, 2015 Greatbatch, Inc. Completes Acquisition of Lake Region Medical Combined Company to be Renamed Integ
Read more →ITGRGreatbatch Announces Pricing of $360 Million of 9.125% Senior Notes due 2023
Greatbatch Announces Pricing of $360 Million of 9.125% Senior Notes due 2023 FRISCO, Texas, October 20, 2015 (GLOBE NEWSWIRE) Greatbatch, Inc. (NYSE: GB) today announced that its wholly-owned subsidiary Greatbatch Ltd. had priced its previously announced private offering of $36
Read more →ITGRGreatbatch Announces Private Offering of $360 Million of Senior Notes in Connection with its Acquisition of Lake Region Medical
Greatbatch Announces Private Offering of $360 Million of Senior Notes in Connection with its Acquisition of Lake Region Medical FRISCO, Texas, October 13, 2015 (GLOBE NEWSWIRE) Greatbatch, Inc. (NYSE: GB) today announced that its wholly-owned subsidiary Greatbatch Ltd. intends
Read more →ITGRAccellent Inc. Consolidated Financial Statements as of and for the Years Ended
Consolidated Financial Statements as of Years Ended January 3, 2015 and December 31, 2013, and Independent Auditors Report Page INDEPENDENT AUDITORS REPORT 1 CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE YEARS ENDED JANUARY 3, 2015 AND DECEMBER 31, 2013: Consol
Read more →ITGRGreatbatch, Inc. Provides Preliminary 2014 Results and 2015 Guidance
Greatbatch, Inc. Provides Preliminary 2014 Results and 2015 Guidance FRISCO, Texas, Jan. 15, 2015 (GLOBE NEWSWIRE) -- Greatbatch, Inc. (NYSE:GB), today provided preliminary 2014 adjusted diluted earnings per share of approximately $2.38 and guidance for 2015. Greatbatch Presiden
Read more →ITGRGreatbatch, Inc. Reports 2013 Fourth Quarter and Full Year Results FRISCO, Texas--(BUSINESS WIRE)
Inc. Reports 2013 Fourth Quarter and Full Year Results FRISCO, Texas--(BUSINESS WIRE)--February 24, 2014--Greatbatch, Inc. (NYSE:GB), today announced results for its fourth quarter and full-year ended January 3, 2014 highlighted by 5% constant currency organic revenue growth
Read more →ITGRJP Morgan Conference January 13-16, 2014 GREATBATCH TEAM Thomas J. Hook President & CEO Michael Dinkins Executive Vice President & CFO Betsy Cowell Vice President Finance & Treasurer FORWARD-LOOKING STATEMENTS We will be
Conference January 13-16, 2014 TEAM Thomas J. Hook President & CEO Michael Dinkins Executive Vice President & CFO Betsy Cowell Vice President Finance & Treasurer FORWARD-LOOKING STATEMENTS We will be making forward-looking statements during today s presentation Please refer to
Read more →Competitive Position
How ITGR ranks across every disease it competes inCompetitive Position is a premium feature
See how ITGR ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial